Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells.

Marion WobserAlexandra WeberAmelie GlunzSaskia TauchKristina SeitzTobias ButelmannSonja HesbacherMatthias GoebelerRené BartzHella KohlhofDavid SchramaRoland Houben

Published in: Journal of hematology & oncology (2019)

We demonstrate that 4SC-202, a drug currently tested in clinical trials, effectively inhibits growth of CTCL cells. The anti-cancer cell activity of 4SC-202 is however not limited to LSD1-inhibition, modulation of histone modifications, and consecutive alteration of gene expression. Indeed, the compound is also a potent microtubule-destabilizing agent.

Keyphrases

induced apoptosis
gene expression
clinical trial
cell cycle arrest
dna methylation
cell death
emergency department
randomized controlled trial
cell proliferation
open label
phase ii
drug induced
phase iii